Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Blue Cross plans are retreating from GLP-1 weight-loss drug coverage after spending hundreds of millions of dollars on the ...

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

The Cigna Group (NYSE: CI )’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...

The agreements cap patients’ monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs ...

An investigation by The Guardian finds the insurance giant UnitedHealth Group quietly paid thousands in bonuses to nursing home facilities that helped it gain Medicare enrollees and reduce ...

Cigna’s Evernorth unit scored a deal with Eli Lilly and Novo Nordisk to make weight loss drugs more affordable for insured ...

The problem was resolved Thursday, when lawmakers sent a $240 million supplemental budget to Governor Maura Healey, which she ...

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the company’s ...